Haichuang Pharmaceutical Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Haichuang Pharmaceutical Co., Ltd. - overview
Established
2013
Location
Chengdu, Sichuan, China
Primary Industry
Pharmaceuticals
About
Established in 2013 and based in Chengdu, China, Haichuang Pharmaceutical Co. , Ltd. is a drug discovery and development company that focuses on therapeutic areas. The company has 10 products under development.
In its current product pipeline, HC-1119 is in two Phase III clinical trials for the treatment of desmoid-resistant prostate cancer; HP501 for the treatment of hyperuricemia and gout has completed a Phase II clinical trial; HP558, a potential therapeutic agent for gastrointestinal tumors, has completed a Phase I clinical trial in Europe and a Phase II clinical trial application has been approved by the NMPA; and HP518, an oral PROTAC agent for AR, is in Phase I clinical trial in Australia. The company has four technology platforms including PROTAC targeted protein degradation technology platform, deuterated drug research and development platform, targeted drug discovery and verification platform, and lead compound optimization and screening platform.
Current Investors
Icon Venture Capital, Haisco Pharmaceutical Group, Hermed Capital
Primary Industry
Pharmaceuticals
Sub Industries
Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.hinovapharma.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Haichuang Pharmaceutical Co., Ltd. - financials
| Fiscal Year Ended | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 |
|---|---|---|---|
| Revenue (USD) | - | - | - |
| % Revenue Growth (YoY) | - | - | - |
| EBITDA (USD) | - | - | - |
| Operating Income (USD) | - | - | - |
| Operating Margin | - | - | - |
| % EBITDA Margin | - | - | - |
| NET Income (USD) | - | - | - |
| % Net Margin | - | - | - |
Haichuang Pharmaceutical Co., Ltd. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| 独立董事 | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.